Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells.

<h4>Background and aims</h4>Liver fibrosis is a major cause of morbidity and mortality. It is characterised by excessive extracellular matrix (ECM) deposition from activated hepatic stellate cells (HSCs). Although potentially reversible, treatment remains limited. Understanding how ECM i...

Full description

Saved in:
Bibliographic Details
Main Authors: James Pritchett, Varinder S Athwal, Emma Harvey, Katherine Martin, Jessica Llewellyn, Philip Ireland, Alexander Nicolaides, Martin J Humphries, Nicoletta Bobola, Neil A Hanley, Karen Piper Hanley
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0100091
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850125445794627584
author James Pritchett
Varinder S Athwal
Emma Harvey
Katherine Martin
Jessica Llewellyn
Philip Ireland
Alexander Nicolaides
Martin J Humphries
Nicoletta Bobola
Neil A Hanley
Karen Piper Hanley
author_facet James Pritchett
Varinder S Athwal
Emma Harvey
Katherine Martin
Jessica Llewellyn
Philip Ireland
Alexander Nicolaides
Martin J Humphries
Nicoletta Bobola
Neil A Hanley
Karen Piper Hanley
author_sort James Pritchett
collection DOAJ
description <h4>Background and aims</h4>Liver fibrosis is a major cause of morbidity and mortality. It is characterised by excessive extracellular matrix (ECM) deposition from activated hepatic stellate cells (HSCs). Although potentially reversible, treatment remains limited. Understanding how ECM influences the pathogenesis of the disease may provide insight into novel therapeutic targets for the disease. The extracellular protein Epimorphin (EPIM) has been implicated in tissue repair mechanisms in several tissues, partially, through its ability to manipulate proteases. In this study, we have identified that EPIM modulates the ECM environment produced by activated hepatic stellate cells (HSCs), in part, through down-regulation of pro-fibrotic Sex-determining region Y-box 9 (SOX9).<h4>Methods</h4>Influence of EPIM on ECM was investigated in cultured primary rat HSCs. Activated HSCs were treated with recombinant EPIM or SOX9 siRNA. Core fibrotic factors were evaluated by immunoblotting, qPCR and chromatin immunoprecipitation (ChIP).<h4>Results</h4>During HSC activation EPIM became significantly decreased in contrast to pro-fibrotic markers SOX9, Collagen type 1 (COL1), and α-Smooth muscle actin (α-SMA). Treatment of activated HSCs with recombinant EPIM caused a reduction in α-SMA, SOX9, COL1 and Osteopontin (OPN), while increasing expression of the collagenase matrix metalloproteinase 13 (MMP13). Sox9 abrogation in activated HSCs increased EPIM and MMP13 expression.<h4>Conclusion</h4>These data provide evidence for EPIM and SOX9 functioning by mutual negative feedback to regulate attributes of the quiescent or activated state of HSCs. Further understanding of EPIM's role may lead to opportunities to modulate SOX9 as a therapeutic avenue for liver fibrosis.
format Article
id doaj-art-202462e452b44d6f83ef982a6e27c81e
institution OA Journals
issn 1932-6203
language English
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-202462e452b44d6f83ef982a6e27c81e2025-08-20T02:34:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0196e10009110.1371/journal.pone.0100091Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells.James PritchettVarinder S AthwalEmma HarveyKatherine MartinJessica LlewellynPhilip IrelandAlexander NicolaidesMartin J HumphriesNicoletta BobolaNeil A HanleyKaren Piper Hanley<h4>Background and aims</h4>Liver fibrosis is a major cause of morbidity and mortality. It is characterised by excessive extracellular matrix (ECM) deposition from activated hepatic stellate cells (HSCs). Although potentially reversible, treatment remains limited. Understanding how ECM influences the pathogenesis of the disease may provide insight into novel therapeutic targets for the disease. The extracellular protein Epimorphin (EPIM) has been implicated in tissue repair mechanisms in several tissues, partially, through its ability to manipulate proteases. In this study, we have identified that EPIM modulates the ECM environment produced by activated hepatic stellate cells (HSCs), in part, through down-regulation of pro-fibrotic Sex-determining region Y-box 9 (SOX9).<h4>Methods</h4>Influence of EPIM on ECM was investigated in cultured primary rat HSCs. Activated HSCs were treated with recombinant EPIM or SOX9 siRNA. Core fibrotic factors were evaluated by immunoblotting, qPCR and chromatin immunoprecipitation (ChIP).<h4>Results</h4>During HSC activation EPIM became significantly decreased in contrast to pro-fibrotic markers SOX9, Collagen type 1 (COL1), and α-Smooth muscle actin (α-SMA). Treatment of activated HSCs with recombinant EPIM caused a reduction in α-SMA, SOX9, COL1 and Osteopontin (OPN), while increasing expression of the collagenase matrix metalloproteinase 13 (MMP13). Sox9 abrogation in activated HSCs increased EPIM and MMP13 expression.<h4>Conclusion</h4>These data provide evidence for EPIM and SOX9 functioning by mutual negative feedback to regulate attributes of the quiescent or activated state of HSCs. Further understanding of EPIM's role may lead to opportunities to modulate SOX9 as a therapeutic avenue for liver fibrosis.https://doi.org/10.1371/journal.pone.0100091
spellingShingle James Pritchett
Varinder S Athwal
Emma Harvey
Katherine Martin
Jessica Llewellyn
Philip Ireland
Alexander Nicolaides
Martin J Humphries
Nicoletta Bobola
Neil A Hanley
Karen Piper Hanley
Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells.
PLoS ONE
title Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells.
title_full Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells.
title_fullStr Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells.
title_full_unstemmed Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells.
title_short Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells.
title_sort epimorphin alters the inhibitory effects of sox9 on mmp13 in activated hepatic stellate cells
url https://doi.org/10.1371/journal.pone.0100091
work_keys_str_mv AT jamespritchett epimorphinalterstheinhibitoryeffectsofsox9onmmp13inactivatedhepaticstellatecells
AT varindersathwal epimorphinalterstheinhibitoryeffectsofsox9onmmp13inactivatedhepaticstellatecells
AT emmaharvey epimorphinalterstheinhibitoryeffectsofsox9onmmp13inactivatedhepaticstellatecells
AT katherinemartin epimorphinalterstheinhibitoryeffectsofsox9onmmp13inactivatedhepaticstellatecells
AT jessicallewellyn epimorphinalterstheinhibitoryeffectsofsox9onmmp13inactivatedhepaticstellatecells
AT philipireland epimorphinalterstheinhibitoryeffectsofsox9onmmp13inactivatedhepaticstellatecells
AT alexandernicolaides epimorphinalterstheinhibitoryeffectsofsox9onmmp13inactivatedhepaticstellatecells
AT martinjhumphries epimorphinalterstheinhibitoryeffectsofsox9onmmp13inactivatedhepaticstellatecells
AT nicolettabobola epimorphinalterstheinhibitoryeffectsofsox9onmmp13inactivatedhepaticstellatecells
AT neilahanley epimorphinalterstheinhibitoryeffectsofsox9onmmp13inactivatedhepaticstellatecells
AT karenpiperhanley epimorphinalterstheinhibitoryeffectsofsox9onmmp13inactivatedhepaticstellatecells